A four-year collaboration between REGENERON PHARMACEUTICALS, INC. and SUMITOMO PHARMACEUTICALS CO., LTD. to develop the Tarrytown, New York partner's brain-derived neurotrophic factor for the Japanese market has progressed to the point that Regeneron licensed Sumitomo Pharmaceuticals to make and market BDNF. That agreement triggered a $5 million payment by the Japanese drug company, which will make additional payments dependent on the achievement of specific milestones and pay royalties on sales of BDNF in Japan. Regeneron and Sumitomo Pharmaceuticals are investigating BDNF for the treatment of amyotrophic lateral sclerosis, better known as Lou Gehrig's disease. Phase I clinical trials started this past spring.
A system for detecting oral cancer, which frequently is related to smoking, is coming to Japan, where the percentage of men who smoke is the highest in the world. OraTest developer ZILA, INC. of Phoenix, Arizona gave NIPPON SHOJI KAISHA, LTD. exclusive marketing rights to the five- minute mouthrinse test. The big drug wholesaler will pay a licensing fee and handle regulatory approval.
The subsidiary of PHARMACIA & UPJOHN, INC. is marketing two antibiotics for dogs to veterinarians. ANTIROBE, a brand of clindamycin hydrochloride sold in 25-milligram capsules, is indicated for the treatment of bacterial infections associated with wounds, abscesses and dental problems as well as for osteomyelitis. LINCOCIN, a lincomycin hydrochlorid product available in 100-mg tablets, is effective against most common gram- positive organisms, particularly streptococci and staphylococci.
An exchange rate of ¥145=$1.00 was used in this report.